Design of next-generation protein therapeutics

Current Opinion in Chemical Biology

Volumn 14, Issue 4, 2010, Pages 520-528

  Caravella, Justin ^a   Lugovskoy, Alexey ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIGEN; FC RECEPTOR; RECOMBINANT ANTIBODY; SCAFFOLD PROTEIN;

ANTIBODY ENGINEERING; ANTIGEN BINDING; BIOCHEMICAL COMPOSITION; BIOMEDICAL ENGINEERING; BIOPHYSICS; DRUG DESIGN; DRUG DISTRIBUTION; DRUG STABILITY; DRUG TARGETING; MOLECULAR RECOGNITION; REVIEW;

ANTIBODIES; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

EID: 77955331645     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2010.06.175     Document Type: Review

References (63)

1. Leader B., Baca Q.J., Golan D.E. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008, 7:21-39.
2. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008, 20:460-470.
3. Stewart-Jones G., Wadle A., Hombach A., Shenderov E., Held G., Fischer E., Kleber S., Nuber N., Stenner-Liewen F., Bauer S., et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A 2009, 106:5784-5788.
4. Lippow S.M., Wittrup K.D., Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 2007, 25:1171-1176.
5. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J.W., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
6. Allan D.G.P. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005, 10:760-761.
7. Talavera A., Friemann R., Gomez-Puerta S., Martinez-Fleites C., Garrido G., Rabasa A., Lopez-Requena A., Pupo A., Johansen R.F., Sanchez O., et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009, 69:5851-5859.
8. Garrett T.P.J., Burgess A.W., Gan H.K., Luwor R.B., Cartwright G., Walker F., Orchard S.G., Clayton A.H.A., Nice E.C., Rothacker J., et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A 2009, 106:5082-5087.
9. Brambell F.W., Hemmings W.A., Morris I.G. A theoretical model of gamma-globulin catabolism. Nature 1964, 203:1352-1354.
10. Oganesyan V., Damschroder M.M., Woods R.M., Cook K.E., Wu H., Dall'Acqua W.F. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009, 46:1750-1755.
11. Yeung Y.A., Leabman M.K., Marvin J.S., Qiu J., Adams C.W., Lien S., Starovasnik M.A., Lowman H.B. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009, 182:7663.
12. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W.L., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Nat Biotechnol 2010, 28:157-159.
13. Cohen-Solal J.F.G., Cassard L., Fridman W., Sautès-Fridman C. Fc gamma receptors. Immunol Lett 2004, 92:199-205.
14. Oganesyan V., Damschroder M.M., Leach W., Wu H., Dall'Acqua W.F. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 2008, 45:1872-1882.
15. Oganesyan V., Gao C., Shirinian L., Wu H., Dall'Acqua W.F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D: Biol Crystallogr 2008, 64:700-704.
16. Zalevsky J., Leung I.W.L., Karki S., Chu S.Y., Zhukovsky E.A., Desjarlais J.R., Carmichael D.F., Lawrence C.E. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009, 113:3735-3743.
17. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009, 10:588-596.
18. Jung S.T., Reddy S.T., Kang T.H., Borrok M.J., Sandlie I., Tucker P.W., Georgiou G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A 2010, 107:604-609.
19. Sazinsky S.L., Ott R.G., Silver N.W., Tidor B., Ravetch J.V., Wittrup K.D. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A 2008, 105:20167-20172.
20. Richards J.O., Karki S., Lazar G.A., Chen H., Dang W., Desjarlais J.R. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008, 7:2517-2527.
21. Senter P.D. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009, 13:235-244.
22. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blättler W.A., Lambert J.M., Chari R.V.J., Lutz R.J., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68:9280-9290.
23. Polson A.G., Calemine-Fenaux J., Chan P., Chang W., Christensen E., Clark S., de Sauvage F.J., Eaton D., Elkins K., Elliott J.M., et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009, 69:2358-2364.
24. Voynov V., Chennamsetty N., Kayser V., Wallny H., Helk B., Trout B.L. Design and application of antibody cysteine variants. Bioconjug Chem 2010, 21:385-392.
25. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
26. Wu C., Ying H., Grinnell C., Bryant S., Miller R., Clabbers A., Bose S., McCarthy D., Zhu R., Santora L., et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007, 25:1290-1297.
27. Wu C., Ying H., Bose S., Miller R., Medina L., Santora L., Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009, 1:339-347.
28. Orcutt K.D., Ackerman M.E., Cieslewicz M., Quiroz E., Slusarczyk A.L., Frangioni J.V., Wittrup K.D. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010, 23:221-228.
29. Michaelson J.S., Demarest S.J., Miller B., Amatucci A., William S., Wu X., Huang F., Phan S., Gao S., Doern A., et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR. MAbs 2009, 1:128-141.
30. Dimasi N., Gao C., Fleming R., Woods R.M., Yao X., Shirinian L., Kiener P.A., Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009, 393:672-692.
31. Bostrom J., Yu S., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
32. Friedman M., Lindström S., Ekerljung L., Andersson-Svahn H., Carlsson J., Brismar H., Gedda L., Frejd F.Y., Ståhl S. Engineering and characterization of a bispecific HER2×EGFR-binding affibody molecule. Biotechnol Appl Biochem 2009, 54:121-131.
33. Ridgway J.B., Presta L.G., Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996, 9:617-621.
34. Jin H., Yang R., Zheng Z., Romero M., Ross J., Bou-Reslan H., Carano R.A.D., Kasman I., Mai E., Young J., et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008, 68:4360-4368.
35. Sheridan C. Pharma consolidates its grip on post-antibody landscape. Nat Biotechnol 2007, 25:365-366.
36. Dumont J.A., Low S.C., Peters R.T., Bitonti A.J. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006, 20:151-160.
37. Peters R.T., Low S.C., Kamphaus G.D., Dumont J.A., Amari J.V., Lu Q., Zarbis-Papastoitsis G., Reidy T.J., Merricks E.P., Nichols T.C., et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010, 115:2057-2064.
38. Van Bockstaele F., Holz J., Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009, 10:1212-1224.
39. Barthelemy P.A., Raab H., Appleton B.A., Bond C.J., Wu P., Wiesmann C., Sidhu S.S. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem 2008, 283:3639-3654.
40. Holt L.J., Basran A., Jones K., Chorlton J., Jespers L.S., Brewis N.D., Tomlinson I.M. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008, 21:283-288.
41. Walker A., Dunlevy G., Rycroft D., Topley P., Holt L.J., Herbert T., Davies M., Cook F., Holmes S., Jespers L., et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel 2010, 23:271-278.
42. Tasumi S., Velikovsky C.A., Xu G., Gai S.A., Wittrup K.D., Flajnik M.F., Mariuzza R.A., Pancer Z. High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proc Natl Acad Sci U S A 2009, 106:12891-12896.
43. Hackel B.J., Kapila A., Wittrup K.D. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 2008, 381:1238-1252.
44. Getmanova E.V., Chen Y., Bloom L., Gokemeijer J., Shamah S., Warikoo V., Wang J., Ling V., Sun L. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 2006, 13:549-556.
45. Dineen S.P., Sullivan L.A., Beck A.W., Miller A.F., Carbon J.G., Mamluk R., Wong H., Brekken R.A. The adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008, 8:352.
46. Huang J., Koide A., Makabe K., Koide S. Design of protein function leaps by directed domain interface evolution. Proc Natl Acad Sci U S A 2008, 105:6578-6583.
47. Huang J., Makabe K., Biancalana M., Koide A., Koide S. Structural basis for exquisite specificity of affinity clamps, synthetic binding proteins generated through directed domain-interface evolution. J Mol Biol 2009, 392:1221-1231.
48. Merz T., Wetzel S.K., Firbank S., Plückthun A., Grütter M.G., Mittl P.R.E. Stabilizing ionic interactions in a full-consensus ankyrin repeat protein. J Mol Biol 2008, 376:232-240.
49. Zahnd C., Kawe M., Stumpp M.T., de Pasquale C., Tamaskovic R., Nagy-Davidescu G., Dreier B., Schibli R., Binz H.K., Waibel R., et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010, 70:1595-1605.
50. Zahnd C., Wyler E., Schwenk J.M., Steiner D., Lawrence M.C., McKern N.M., Pecorari F., Ward C.W., Joos T.O., Plückthun A. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007, 369:1015-1028.
51. Takacs Z., Toups M., Kollewe A., Johnson E., Cuello L.G., Driessens G., Biancalana M., Koide A., Ponte C.G., Perozo E., et al. A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A 2009, 106:22211-22216.
52. Wang N., Smith W.F., Miller B.R., Aivazian D., Lugovskoy A.A., Reff M.E., Glaser S.M., Croner L.J., Demarest S.J. Conserved amino acid networks involved in antibody variable domain interactions. Proteins 2009, 76:99-114.
53. Borras L., Gunde T., Tietz J., Bauer U., Hulmann-Cottier V., Grimshaw J.P.A., Urech D.M. Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem 2010, 285:9054-9066.
54. Saerens D., Conrath K., Govaert J., Muyldermans S. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol 2008, 377:478-488.
55. Gong R., Vu B.K., Feng Y., Prieto D.A., Dyba M.A., Walsh J.D., Prabakaran P., Veenstra T.D., Tarasov S.G., Ishima R., et al. Engineered human antibody constant domains with increased stability. J Biol Chem 2009, 284:14203-14210.
56. Wu H., Pfarr D.S., Johnson S., Brewah Y.A., Woods R.M., Patel N.K., White W.I., Young J.F., Kiener P.A. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007, 368:652-665.
57. Chennamsetty N., Voynov V., Kayser V., Helk B., Trout B.L. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 2009, 106:11937-11942.
58. Chennamsetty N., Helk B., Voynov V., Kayser V., Trout B.L. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 2009, 391:404-413.
59. Pepinsky R.B., Silvian L., Berkowitz S., Farrington G.K., Lugovskoy A., Walus L., Eldredge J., Capili A., Mi S., Graff C.P., et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 2010, 19:954-966.
60. Almagro J.C., Fransson J. Humanization of antibodies. Front Biosci 2008, 13:1619-1633.
61. Bernett M.J., Karki S., Moore G.L., Leung I.W.L., Chen H., Pong E., Nguyen D.T., Jacinto J., Zalevsky J., Muchhal U.S., et al. Engineering fully human monoclonal antibodies from murine variable regions. J Mol Biol 2010, 396:1474-1490.
62. Kügler M., Stein C., Schwenkert M., Saul D., Vockentanz L., Huber T., Wetzel S.K., Scholz O., Plückthun A., Honegger A., et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel 2009, 22:135-147.
63. Honegger A., Malebranche A.D., Röthlisberger D., Plückthun A. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng Des Sel 2009, 22:121-134.